Vivos (RDGL) Total Liabilities: $0.25 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Vivos Total Liabilities?

Vivos RDGL -3.38% Total Liabilities is $0.25 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Vivos's Total Liabilities for the quarter that ended in Mar. 2026 was $0.25 Mil.

Vivos's quarterly Total Liabilities increased from Sep. 2025 ($0.11 Mil) to Dec. 2025 ($0.21 Mil) and increased from Dec. 2025 ($0.21 Mil) to Mar. 2026 ($0.25 Mil).

Vivos's annual Total Liabilities declined from Dec. 2023 ($0.25 Mil) to Dec. 2024 ($0.09 Mil) but then increased from Dec. 2024 ($0.09 Mil) to Dec. 2025 ($0.21 Mil).


Vivos Total Liabilities Historical Data

* Premium members only.

The historical data trend for Vivos's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivos Total Liabilities Chart

Vivos Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.08 0.25 0.09 0.21

Vivos Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.10 0.11 0.21 0.25

Vivos Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Vivos's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1.868-1.661
=0.21

Vivos's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=0.172+(0.081+1.3877787807814E-17
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=0.25

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=2.951-2.697
=0.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $0.25 Mil mean?
Vivos (RDGL) has a Total Liabilities of $0.25 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vivos and its competitors.
Is Vivos' Total Liabilities too high?
Vivos' current Total Liabilities is $0.25 Mil.
How does Vivos' Total Liabilities compare to ARAY and FOFA?
Vivos' Total Liabilities of $0.25 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Medical Devices & Instruments company?
A good Total Liabilities depends on the Medical Devices & Instruments industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Vivos and its competitors. Vivos's current Total Liabilities is $0.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivos stock overvalued right now?
Vivos (RDGL) has a current Total Liabilities of $0.25 Mil. The current Total Liabilities is $0.25 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Vivos (RDGL), the current Total Liabilities is $0.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivos Business Description

Address 1030 N Center Parkway, Kennewick, WA, USA, 99352
Vivos Inc is a radiation oncology medical device company engaged in the development of its yttrium-90 (Y-90) based precision radionuclide therapy devices. Its portfolio includes RadioGel Precision Radionuclide Therapy (Human Division) for treating solid tumors and positive surgical margins in humans and IsoPet (Animal Division) for treating solid tumors in animals. Vivos also sells PLGA-g-PEG polymers and PrecisionGel, a hydrogel polymer platform for delivering active pharmaceutical ingredients and therapeutic agents. The company currently mainly operates in the United States.